( omax is currently approved in the U.S. ...)Acuity One-Year Findings Meet All Primary Endpoints in Favor of,Angiomax (Bivalirudin) Alone Treatment Group,Health

omax is currently approved in the U.S. and the European Union, as well as several other territories. Angiomax is a direct thrombin inhibitor with a naturally reversible mechanism of action. In clinical trials, Angiomax has demonstrated efficacy plus reductions in bleeding complications compared to heparin as the foundation anticoagulant in the contemporary catheterization lab setting. These reductions in bleeding complications remain evident even in high-risk patients.

In the U.S., Angiomax is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA) and with provisional GPIIb/IIIa inhibition in patients undergoing PCI. Angiomax is also indicated in patients with, or at risk of, HIT/HITTS undergoing PCI. Angiomax is intended for use with aspirin. The most common adverse events for Angiomax in clinical trials comparing Angiomax and heparin were back pain, pain, nausea, headache, and hypotension. The incidence of these adverse events was comparable in both the Angiomax and heparin groups in these trials. An unexplained fall in blood pressure or hematocrit, or any unexplained symptom, should lead to serious consideration of a hemorrhagic event and cessation of Angiomax administration. Angiomax is contraindicated in patients with active major bleeding or hypersensitivity to Angiomax or its components. Please see full prescribing information available at http://www.angiomax.com.

Investor Conference Call

The Medicines Company management has scheduled a conference call with investors to discuss the late-breaking data on Monday, March 26 at 6:00 p.m. Eastern Time (5:00 p.m. Central Time in New Orleans). The conference call will be available via phone and webcast. The webcast can be accessed at The Medicines Company website at http://www.themedicinescompany.com
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
5. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
6. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
7. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
8. EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3 Clinical Trial at 47th Annual NCDEU Meeting
9. Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
10. Prana Biotechnology Presents New Key Findings on PBT2
11. Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD